Clinical Research Directory
Browse clinical research sites, groups, and studies.
CAIX PET/ CT Guided Radiation Therapy in CcRCC.
Sponsor: Peking University First Hospital
Summary
This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET/CT imaging (FDG PET/CT and a CAIX-targeted PET/CT) to map disease sites. When feasible, PET/CT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: \~70).
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2025-11-01
Completion Date
2030-12-31
Last Updated
2026-04-20
Healthy Volunteers
No
Interventions
PETCT-guided radiation therapy
PETCT-guided radiation therapy: All patients will undergo both FDG PET/CT and CAIX PET/CT. Radiotherapy will be planned and delivered based on the imaging findings, with the goal of achieving the most comprehensive feasible (all-site) coverage whenever appropriate.
Locations (1)
Peking University First Hospital
Beijing, Beijing Municipality, China